Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates
![Value, Access, and Incentives for Innovation - Policy Perspectives on Alternative Models for Pharmaceutical Rebates](https://www.ohe.org/wp-content/uploads/2019/03/Value-Access-and-Incentives-for-Innovation-Policy-Perspectives-on-Alternative-Models-for-Pharmaceutical-Rebates.jpg)
Cell and gene therapies offer substantial therapeutic benefits but are expensive and often have a limited evidence base at launch. There are concerns over affordability and long-term cost-effectiveness, as well as uncertainty as to whether their value is accurately captured by current HTA methods.